Insmed is trading up 19.41% at $115.80 in pre-market on October 29 after third-quarter revenue beat estimates and the company raised the lower end of its full-year revenue outlook.
- Revenue was $524.4 million, driven by strong BRINSUPRI adoption.
- The $0.46-per-share loss was wider than expected amid commercial and clinical investment; the results discussion is scheduled for October 29 at 8:00 a.m. ET.
- The prior close was $96.98; no pre-market volume information was provided.